Geistlich Pharma AG

Proven, patented technology drives new company’s entry into aesthetic skin rejuvenation and wound-care regenerative markets FRANKLIN, Tenn.--(BUSINESS WIRE)-- Dr. Samuel Lynch, DMD and DMSc, a serial biotechnology entrepreneur, has announced the launch of Lynch Regenerative Medicine, Inc. (LRM), a new advanced biotherapeutics skincare company targeting unmet clinical needs in both the aesthetic and advanced wound care markets. LRM is leveraging its proven technology, rhPDGF (Manufactured Platelet-Derived Growth Factor), the body’s most important protein promoting healing, for treatment of major underserved skin conditions, targeting improved aesthetics and healing of skin wounds. This market exceeds 41 million patients and $100 billion in annual treatment spends. Lynch’s patented technology is a proprietary form of the human body’s own healing factor that stimulates cell and tissue growth and improved blood supply, leading to improved skin appearance and health. The technology is already employed in four FDA-approved products used in orthopedics and oral surgery. Lynch discovered the therapeutic benefits of this natural protein, and has patented and led the development of multiple novel products based on the protein in companies he has founded and led. The foundation of LRM is a natural progression of Lynch’s passion spanning more than two decades developing and delivering clinical solutions that have improved the lives of millions of patients. “I am thrilled to announce the formation of Lynch Regenerative Medicine,” said Lynch. “Skin is the largest organ in the body, and is therefore our biggest opportunity yet to utilize the powers of rhPDGF to improve the emotional and physical health of people around the world. By harnessing the power of our highly successful regenerative technology to naturally stimulate growth of the person’s own stem cells, we have the potential to revolutionize both cosmetic and prescription-strength skin therapies and thereby help millions of patients attain healthier, more attractive appearance and heal skin injuries faster.” Lynch received his Doctorate of Medical Sciences from Harvard University Medical School, where he initially developed the technology. He founded and subsequently sold two companies, BioMimetic Therapeutics and Lynch Biologics, both of which use rhPDGF in FDA-approved therapies for tissue and skeletal regeneration. Lynch is also the co-founder and chairman of BioTN and a founding board member of Vanderbilt University Medical Center. “LRM’s products have the potential to disrupt the skincare industry as we know it today,” said Ben Perkins, managing partner of pHPartners, an investment banking firm specializing in life sciences transactions. “LRM’s rhPDGF has been tested, verified and FDA-approved as a revolutionary regenerative-care product for millions of patients around the world in multiple indications. We are excited to work with LRM as they bring this amazing technology to skincare. People who need comprehensive skincare will now have a better option to improve their youthful appearance and heal their skin injuries.” LRM is in the process of building manufacturing capacity for large-scale, commercial production for its aesthetics and wound care therapies, and is currently evaluating its pure, natural products in a variety of applications to improve skincare. The new products are not yet available to the public. For more information visit . About Lynch Regenerative Medicine Founded in 2023 by Dr. Samuel Lynch, Lynch Regenerative Medicine is a biotherapeutics company pioneering innovative treatments to revolutionize skincare, including rejuvenation to achieve optimum aesthetics and regeneration to achieve improved healing of skin wounds. Its core technology utilizes patented formulations of rhPDGF (Manufactured Platelet-Derived Growth Factor), the body’s most important healing protein, to improve aesthetics and healing. LRM is currently evaluating its natural, pure protein technology in a variety of skin applications. For investor relations, please contact us at contact@LynchRegen.com. View source version on businesswire.com: Contacts contact@lynchregen.com Source: Lynch Regenerative Medicine, Inc. View this news release online at:

DUBLIN--( BUSINESS WIRE )--The "Dental Biomaterial Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering. The global dental biomaterial market is expected to grow at a CAGR of 10.38% over the forecast period to reach a total market size of US$14.296 billion by 2027, increasing from US$7.163 billion in 2020. Companies Mentioned Straumann AG Royal DSM Geistlich Pharma AG ZimVie Inc 3M Company Dentsply Sirona, Inc Kuraray Co., Ltd Mitsui Chemicals, Inc DMP Dental Industry S.A Dental biomaterials include all types of natural and biocompatible synthetic materials used to restore damaged and decayed teeth. The increasing prevalence of dental disorders coupled with the rising penetration of dental implants is expected to drive the growth of the market during the forecast period. However, stringent regulation and the clinical process are anticipated to restrain the growth of the market in the coming years. Dental implants and prosthetics are mostly used either for filling oral cavities or replacing them with a concrete solution and according to the World Health Organization, more than 3 billion people in the world are affected by oral health problems. A dental implant is a kind of oral prosthetic in which the gum is opened and in the cavity is positioned a prosthetic crown. Planning the position and number of implants is key to the long-term health of the prosthetic since biomechanical forces created during chewing can be significant. The growing geriatric population is driving the growth of the market The global population is ageing, and every country is experiencing growth in the old age proportion of elderly people in the total population. Poor oral health among older people is evident in a high level of tooth loss, and all types of periodontal disease. According to the recent report titled World Population Prospects by the United Nations, by 2050, one in every six people in the world will be over age 65 (16%), from one in 11 in 2019 (9%) and the number of people aged 80 years or above is projected to triple, from 143 million in 2019 to 426 million in 2050. Material analysis By material, the dental biomaterial market has been segmented into metallic biomaterials, ceramic biomaterials, and polymeric biomaterials, among others. The metallic biomaterial segment is projected to hold a significant share, owing to the benefits offered by titanium material, such as high biocompatibility, strength, rigidity, greater strain-bearing capacity, and greater corrosion resistance properties. Application insight By application, the dental biomaterial market is segmented based on implantology, prosthodontics, and orthodontics, among other applications. The implantology application segment accounted for a significant share of the market on account of the increasing penetration of dental implants in developing countries like China, India, and Brazil. In addition, the rising demand for cosmetic dentistry, expanding dental tourism in emerging markets, coupled with increasing disposable incomes in developing countries, are further expected to boost the growth of the market in the coming years. North America will hold a significant share in the market over the forecast period By geography, the dental biomaterial market is segmented into North America, South America, Europe, the Middle East and Africa, and the Asia Pacific. The North American region is expected to hold a significant share in the market owing to the presence of major players coupled with the growing geriatric population. In Europe, favourable government initiatives on oral healthcare, combined with increased adoption of dental biomaterials for the fabrication of implants and other dental products, are expected to drive the regional market in the coming years. Besides, rising disposable income and the growing number of dental hospitals, the market for dental biomaterials is anticipated to witness exponential growth in the Asia Pacific region. Market Segmentation: By Material Metallic Biomaterials Titanium Stainless Steel Other Ceramic Biomaterials Polymeric Biomaterials By Application Implantology Prosthodontics Orthodontics By End-user Hospitals Clinics Academies and Research Laboratories By Geography North America United States Canada Mexico South America Brazil Argentina Europe Germany Spain United Kingdom France Middle East and Africa Saudi Arabia UAE Asia Pacific China Japan India Indonesia Thailand Taiwan For more information about this report visit https://www.researchandmarkets.com/r/o96y12

This Geistlich Select product line brings an added confidence to regenerative procedures Introducing vallos from Geistlich North America. (Credit: PR Newswire/ Geistlich Pharma North America, Inc.) Geistlich Pharma North America Inc. is setting the pace for expanded treatment options with the introduction of vallos, our first demineralized allograft. With two formulations for treatment flexibility, vallos granules are ideally suited for smaller routine defects while vallos f fibers are designed for larger more complex defects. This Geistlich Select product line brings an added confidence to regenerative procedures, with: Verified osteoinductive potential in every lot Consistent product quality Proven regenerative capacity by exhibiting all five elements of bone formation1 Vital bone after 18-20 weeks Geistlich Select: Geistlich is proud of the quality and safety of its products and consistently employs rigorous scientific validation and strict manufacturing processes. Extensive research and collaboration have created a partnership to bring you select allograft materials designed for clinical versatility and success. Demineralized vallos and vallos f offer clinicians more options to enhance their ability to manage a variety of clinical indications and are the first products to become part of the Geistlich Select family. “We are excited to bring these first allograft innovations to clinicians, which provides them with new options for their regenerative procedures. We will be expanding our allograft product line with additional solutions in the near future, as part of our Geistlich Select family,” said Les Burrows, General Manager of Geistlich Pharma North America. Source: Company Press Release